Home > Analytics > SOTAC PHARMACEUTICALS

SOTAC PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM :      NSE : SOTAC    
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward
Pledged Shares : NA
Dec 05,2024
Price(EOD): ₹ 110.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 121.77 Cr
Value of ₹ 1 Lac invested in SOTAC PHARMACEUTICALS
on Apr 13,2023 (price: ₹ 120.75)

₹ 1 L

₹ 0.92 L

1W : -3.7% 1M : -15.3% 1Y : -16.9%
COMMUNITY POLL
for SOTAC PHARMACEUTICALS
Please provide your vote to see the results
Industry Peers & Returns1W1M1Y
SOTAC PHARMACEUTICALS -3.7% -15.3% -16.9%
SUN PHARMACEUTICAL INDUSTRIES 1.6% 0.1% 46.2%
CIPLA -2.3% -5.4% 24.4%
DR REDDYS LABORATORIES 3.2% -2.2% 5.8%
ZYDUS LIFESCIENCES 1.3% -2.6% 51.8%
DIVIS LABORATORIES -1.2% 3.4% 65%
MANKIND PHARMA 2.2% -4.2% 35.5%
TORRENT PHARMACEUTICALS 1.1% 5.1% 55.7%
LUPIN 3.7% -2.9% 62.1%

FUNDAMENTAL ANALYSIS OF SOTAC PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Jun2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF SOTAC PHARMACEUTICALS

 
Valuation Score
[As on : Dec 05,2024 ]

Ratio Consolidated
P/E
P/B
P/S
32.34
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 3.78 Cr
[Latest Qtr - Jun2024 - Consolidated Results ]

2.7
P/B Calculated based on Book Value of Rs 45.26 Cr
[Latest Year - Mar2024 - Consolidated Results ]

1.28
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 95.61 Cr
[Latest Qtr - Jun2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 8% undervalued companies ! Discover More →

FAIR VALUE OF SOTAC PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
296%
465%
-

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SOTAC PHARMACEUTICALS



SOTAC PHARMACEUTICALS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SOTAC PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0.23
0.93
1.04
0.73
0.55
2.21
1.12
1.29
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SOTAC PHARMACEUTICALS

Pledged Promoter Shares
NA

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SOTAC PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-1.93%
-24.07%
-11.8%
53.65%
27.07%
15.48%
9.06%
150.65%
QtrlyTrend
2
Latest Qtr: Jun2024
Quarterly Result Analysis →


SOTAC PHARMACEUTICALS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about SOTAC PHARMACEUTICALS


Is SOTAC PHARMACEUTICALS good for long term investment?

As on Dec 05,2024, the Fundamentals of SOTAC PHARMACEUTICALS look Poor and hence it may not be good for long term investment ! See Financial Performance of SOTAC PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SOTAC PHARMACEUTICALS UnderValued or OverValued?

As on Dec 05,2024, SOTAC PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SOTAC PHARMACEUTICALS ?

As on Dec 05,2024, the Intrinsic Value of SOTAC PHARMACEUTICALS is Rs. 23.77 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 27.93
Fair Value [Median EV / Sales Model] : Rs. 19.60
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of SOTAC PHARMACEUTICALS : Rs. 23.77

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is SOTAC PHARMACEUTICALS trading at a Premium or Discount?

As on Dec 05,2024, SOTAC PHARMACEUTICALS is trading at a Premium of 366% based on the estimates of Median Intrinsic Value!